



LEADING A NEW ERA

in rapid, on-the-spot testing solutions



MBIO IS DISRUPTING THE \$70B LAB-TESTING BUSINESS, FIRST IN VETERINARY AND ENVIRONMENTAL, AND NOW LEVERAGING THOSE SUCCESSES INTO HEALTHCARE MARKETS:

Veterinary:

Broad menu, companion animal testing in the clinic

Environmental (Water):

Harmful algal blooms: Water supply, recreational, fisheries

Human Clinical:

ER/Urgent Care: Cardiac markers and sepsis

Retail Clinic: Wellness and Chronic Care monitoring (Thyroid, etc.)

Molecular: STD/Flu testing

Homeland Security: Rapid screening/triage for domestic incidents

LIGHTDECK® PLATFORM BENEFITS:



Multiplexing:

Cartridges can be configured to measure more than 50 analytes



Speed and Ease of Use:

Many assays can be completed in minutes in a simple “load-and-go” workflow

Sensitivity:

Delivering the sensitivity of multi-step laboratory protocols (e.g., ELISA)



Quantitation:

Device output is a quantitative digital measure of each signal

Built-In Quality Control:

MBio cartridges incorporate multiple parallel controls that assure quality of every test result



Low-Cost:

Designed with manufacturing in mind, MBio’s disposable cartridges are competitive in all markets

LIGHTDECK® TECHNOLOGY

At the core of all MBio systems is our patented LightDeck® technology, a powerful fluorescence assay illumination and imaging approach, based on planar waveguides. Waveguides have been proven by the scientific community for years to be an excellent approach for uniquely sensitive assays, and MBio's scientists and engineers have created key, patent-protected advances that solve previous reproducibility and cost challenges.

The strength of the platform has been proven across several applications; including companion animal diagnostics in the veterinary clinic, and water source testing for harmful algae blooms. Human clinical efforts include rapid detection of cardiac markers for acute care, with our partner Brava Diagnostics, chronic care and wellness monitoring, and acute infection testing with DARPA.



I.P. SUMMARY

MBio has invested heavily in patent protection of its platform. The company holds 29 U.S. and international patents on its core technology with additional applications in prosecution worldwide.

PLATFORM LICENSING MODEL

MBio is executing on its strategy of technology licensing partnerships, while ramping up manufacturing capacity to enable commercialization efforts of our partners.

We work with our partners to develop dedicated assays for the required markers and customize instruments to give the desired user experience. This allows us to serve our customers on two levels: we meet the end-user desire for fast, simple, and comprehensive testing on-the-spot and we enable our partners to deliver unique products with high performance and low cost of manufacturing.



MBio is a privately held company based in Boulder, Colorado, USA

Leadership

CHRISTOPHER J. MYATT, PH.D.
Chief Executive Officer and Director

MICHAEL J. LOCHHEAD, PH.D.
Chief Operating Officer

Board of Directors

MILTON CHANG, PH.D.
Director

ROBERT J. SILVERMAN
Director

ANDY DRENICK
Director

Collaborators

DR. ROBERT SCHOOLEY
Head of UCSD Infectious Disease

DR. CONSTANCE BENSON
Head UCSD Antiviral Research Center

DR. CHRIS ELLIOTT
Director Institute for Food Security,
Queen's University Belfast

DR. HECTOR WONG
Director of Critical Care Medicine,
Cincinnati Children's Hospital

Business Advisors

SALLY HATCHER
Co-founder and Legal Counsel

NICK TRAGGIS
I.P. Licensing / Growth Strategist

Contact:

5603 Arapahoe Avenue, Suite 1
Boulder, CO 80303, USA
Phone (303) 952-2905
info@mbiodx.com | www.mbiodx.com